p110: driving and neurodegenerative diseases

Authors

mostafa modarres mousavi shefa neuroscience research center, khatam alanbia hospital, tehran, iran.

maryam jafarian a. shefa neuroscience research center, khatam alanbia hospital, tehran, iran. b. school of advanced technologies in medicine, tehran university of medical sciences, tehran, iran.

sajad sahab negah shefa neuroscience research center, khatam alanbia hospital, tehran, iran.

arezou eshaghabadi shefa neuroscience research center, khatam alanbia hospital, tehran, iran.

abstract

the proportion of elderly in the general population is rising, resulting in greater numbers of drivers with neurodegenerative disorders such as alzheimer’s disease (ad) and parkinson’s disease (pd). alzheimer’s disease is a progressive neurodegenerative disorder typified by memory impairment with executive dysfunction, motor problems, and/or language difficulties. parkinson’s disease is a progressive neurodegenerative disease that impairs ability to execute conscious physical movement in addition to other motor functions. what is more, mood disturbances may occur as well. however, pd appears to be associated with decreased driving and increased crashes, especially in those with worse motor and cognitive dysfunction. a review panel found that drivers with mild cognitive impairment (mci)-very mild ad (clinical dementia rating scale [cdr]=0.5) - have impairments similar to drivers aged 16–21 or those driving under the influence of alcohol at a blood alcohol concentration<0.08%. they were also recommended to reassess dementia severity and driving fitness every 6 months, but quit driving in mild ad (cdr=1) due to history of increased crashes and poor driving performance. in conclusion, medical diagnosis or a clinician’s assessments alone are not accurate enough to determine driving competence in those with dementia. although neuropsychological tests help them to understand associations of driver performance with cognitive impairment, a general lack of validated cut off scores makes it impossible to employ these tests in a standardized fashion to advice patients. furthermore, there are no established guidelines on driver’s follow-up timing with mild dementia recommendations range from 6 months or less than a year. thus, medical diagnosis or age alone is not reliable enough to predict driver safety, crashes, or revoke the driving privileges of these drivers. in addition, outlining the evolution of driving safety, understanding the mechanisms of driving impairment, and developing a reliable and efficient standardized test battery for prediction of driver safety in neurodegenerative disorder informed healthcare providers to advise their patients about neurodegenerative disorders with more certainty, affected policy, and develop rehabilitative measures for driving.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

P110: Driving and Neurodegenerative Diseases

لطفاً به چکیده انگلیسی مراجعه شود.

full text

Exosomes: Future Perspective in Neurodegenerative Diseases

Neurodegeneration is a progressive and irreversible loss of neuronal cells in specific regions of the brain. Alzheimer Diseases (AD) Parkinson Disease (PD) are the most common forms of neurodegenerative diseases in older people. Exosomes are extracellular nanovesicles that have a key role in physiological processes such as intercellular communication, cell migration, angiogenesis, and anti-tumo...

full text

Aquaporins and Neurodegenerative Diseases

Aquaporins (AQPs) are a family of widely distributed membrane-inserted water channel proteins providing a pathway for osmotically-driven water, glycerol, urea or ions transport through cell membranes and mechanisms to control particular aspects of homeostasis. Beside their physiological expression patterns in Central Nervous System (CNS), it is conceivable that AQPs are also abnormally expresse...

full text

Inflammation and neurodegenerative diseases.

The decline in mental fitness associated with Alzheimer disease is accompanied by physical changes in the brain, including the development of characteristic plaques and neurofibrillary tangles, but the pathogenesis of those changes is not clear. Recent work suggests that the activation of microglia in response to injury, illness, aging, or other causes begins a cascade of events that can best b...

full text

neurodevelopmental basis of neurodegenerative diseases

the human brain is composed of several interconnected, functionally distinct structures and much debate has surrounded the basic question of how these structures evolve. brain development begins in early gestation. between 4 weeks and 9 months, brain undergoes rapid development. there are six stages of nervous system development. brain increases connections between birth and 21 years of age. ab...

full text

The lysosome and neurodegenerative diseases.

It has long been believed that the lysosome is an important digestive organelle. There is increasing evidence that the lysosome is also involved in pathogenesis of a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Abnormal protein degradation and deposition induced by lysosomal dysfunction may be...

full text

My Resources

Save resource for easier access later


Journal title:
مجله علوم اعصاب شفای خاتم

جلد ۲، شماره ۴، صفحات ۱۶۰-۱۶۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023